TY - JOUR T1 - Cross border, highly individualised treatment of a patient with challenging extensively drug-resistant tuberculosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.02490-2017 SP - 1702490 AU - Onno W. Akkerman AU - Floris Grasmeijer AU - Wiel C.M. de Lange AU - Huib A.M. Kerstjens AU - Gerard de Vries AU - Mathieu S. Bolhuis AU - Jan-Willem Alffenaar AU - Henderik W. Frijlink AU - Grace Smith AU - Roger Gajraj AU - Rina de Zwaan AU - Paul Hagedoorn AU - Martin Dedicoat AU - Dick van Soolingen AU - Tjip S. van der Werf Y1 - 2018/01/01 UR - http://erj.ersjournals.com/content/early/2018/02/08/13993003.02490-2017.abstract N2 - Extensively drug-resistant tuberculosis (XDR-TB) is defined by resistance to isoniazid, rifampicin, any fluoroquinolone and at least one of the three second line injectable drugs, such as amikacin. Drugs toxicity and duration impair adherence to treatment and outcome is rather poor [1]. We report on a particularly challenging XDR-TB patient with persistent non-adherence to treatment and an exceptionally complex drug susceptibility pattern.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Akkerman has nothing to disclose.Conflict of interest: Dr. Grasmeijer reports personal fees from PureIMS B.V., outside the submitted work.Conflict of interest: Dr WCM de Lange has no conflict of interestConflict of interest: Dr. Kerstjens has nothing to disclose.Conflict of interest:Gerard de VriesConflict of interest: Dr. Bolhuis has nothing to disclose.Conflict of interest: Dr. Alffenaar has nothing to disclose.Conflict of interest: Dr. Frijlink reports In addition, Dr. Frijlink has a patent A breath actuated dry powder inhaler, Appl nr WO 2015/187025 A1 pending.Conflict of interest: Dr. Smith has nothing to disclose.Conflict of interest: Dr Roger Gajraj has nothing to disclose.Conflict of interest: Ms. R. de Zwaan has nothing to disclose.Conflict of interest: Dr. Hagedoorn reports In addition, Dr. Hagedoorn has a patent Twincer pending.Conflict of interest: Dr. Dedicoat has nothing to disclose.Conflict of interest: Dick van SoolingenConflict of interest: Dr. van der Werf reports and Principal Investigator of RUTI therapeutic vaccine trial, sponsored in part by Archivel, Badelona, Catalunya / Spain; ER -